Shares of EDGE MEDICAL-B (HKEX: 02675) rose more than 6% in early trading. As of writing, the stock is up 5%, trading at HK$39.92, with a turnover of HK$19.9371 million.

Analysts point out that after years of clinical validation, the performance of domestically produced surgical robots has gained widespread recognition. In an environment of increasingly intense price competition domestically, Chinese companies are accelerating their overseas expansion plans.

Laparoscopic surgical robots are leading this overseas push, with companies like MicroPort setting an example. To date, the cumulative global commercial installations of such robots have exceeded 140 units, marking a stage of scaled-up deployment. Companies including EDGE MEDICAL and Sizherui have also obtained CE certification, initiating their own international expansion journeys.

A research report highlighted that EDGE MEDICAL-B can provide comprehensive laparoscopic robotic solutions. The report noted that the company's commercialization has accelerated since 2025. Its multi-port surgical robot has received market certifications in the European Union, Brazil, Mexico, and other regions, and installations have been completed in markets including Pakistan, Georgia, Brazil, Nigeria, and Uzbekistan. Notably, at the SIUT facility in Pakistan, the installed system has performed over 150 surgeries within six months.